Risk stratification for positive lymph nodes in prostate cancer

Joseph A. Pettus, Timothy Masterson, E. Jason Abel, Richard G. Middleton, Robert A. Stephenson

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose: To evaluate the risk of positive lymph nodes using preoperative clinical parameters. Methods and Materials: We reviewed our prospectively collected database for all patients who received RRP and PLND between January 1993 and November 2005 as primary therapy for prostate cancer. We excluded patients who had hormonal ablation or radiation therapy prior to surgery and patients with missing PSA, clinical stage, or biopsy Gleason score. We evaluated risk for nodal disease using the following definitions: low risk: PSA ≤10 ng/mL, clinical stage ≤T2a, and Gleason score ≤6; intermediate risk: PSA 10 to 20 ng/mL, clinical stage ≥T2b, or Gleason score of 7; and high risk: PSA ≥20 ng/mL, or clinical stage ≥T2c, or Gleason score ≥8. Logistic regression was used to determine the association between the risk groups and pathologic lymph node involvement, and a receiver operating characteristics (ROC) curve was constructed to evaluate the performance of the stratification scheme in detecting nodal disease. Results: A total of 760 patients with 43 (5.7%) patients with node-positive disease were available for analysis. Risk classification was significantly associated with positive nodes (P <0.001), even after controlling for year of surgery and age. The area under the ROC curve was 0.77 (95% CI: 0.69, 0.83). Omitting PLND in the low-risk group would have spared 368 (49.2%) of the entire cohort with a false-negative rate of 5/369 (1.3%) for the low-risk group, and 5/760 (0.7%) for the entire cohort. Sensitivity was 88.4%, and negative predictive value was 98.7%. Conclusion: Patients can be risk stratified for node-positive disease and potentially excluded from lymphadenectomy with minimal risk.

Original languageEnglish (US)
Pages (from-to)1021-1025
Number of pages5
JournalJournal of Endourology
Volume22
Issue number5
DOIs
StatePublished - May 1 2008
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Lymph Nodes
Neoplasm Grading
ROC Curve
Lymph Node Excision
Radiotherapy
Logistic Models
Databases
Biopsy

ASJC Scopus subject areas

  • Urology

Cite this

Pettus, J. A., Masterson, T., Abel, E. J., Middleton, R. G., & Stephenson, R. A. (2008). Risk stratification for positive lymph nodes in prostate cancer. Journal of Endourology, 22(5), 1021-1025. https://doi.org/10.1089/end.2007.0129

Risk stratification for positive lymph nodes in prostate cancer. / Pettus, Joseph A.; Masterson, Timothy; Abel, E. Jason; Middleton, Richard G.; Stephenson, Robert A.

In: Journal of Endourology, Vol. 22, No. 5, 01.05.2008, p. 1021-1025.

Research output: Contribution to journalArticle

Pettus, JA, Masterson, T, Abel, EJ, Middleton, RG & Stephenson, RA 2008, 'Risk stratification for positive lymph nodes in prostate cancer', Journal of Endourology, vol. 22, no. 5, pp. 1021-1025. https://doi.org/10.1089/end.2007.0129
Pettus, Joseph A. ; Masterson, Timothy ; Abel, E. Jason ; Middleton, Richard G. ; Stephenson, Robert A. / Risk stratification for positive lymph nodes in prostate cancer. In: Journal of Endourology. 2008 ; Vol. 22, No. 5. pp. 1021-1025.
@article{e72911ed73a64d468bde4dc7f68791ed,
title = "Risk stratification for positive lymph nodes in prostate cancer",
abstract = "Purpose: To evaluate the risk of positive lymph nodes using preoperative clinical parameters. Methods and Materials: We reviewed our prospectively collected database for all patients who received RRP and PLND between January 1993 and November 2005 as primary therapy for prostate cancer. We excluded patients who had hormonal ablation or radiation therapy prior to surgery and patients with missing PSA, clinical stage, or biopsy Gleason score. We evaluated risk for nodal disease using the following definitions: low risk: PSA ≤10 ng/mL, clinical stage ≤T2a, and Gleason score ≤6; intermediate risk: PSA 10 to 20 ng/mL, clinical stage ≥T2b, or Gleason score of 7; and high risk: PSA ≥20 ng/mL, or clinical stage ≥T2c, or Gleason score ≥8. Logistic regression was used to determine the association between the risk groups and pathologic lymph node involvement, and a receiver operating characteristics (ROC) curve was constructed to evaluate the performance of the stratification scheme in detecting nodal disease. Results: A total of 760 patients with 43 (5.7{\%}) patients with node-positive disease were available for analysis. Risk classification was significantly associated with positive nodes (P <0.001), even after controlling for year of surgery and age. The area under the ROC curve was 0.77 (95{\%} CI: 0.69, 0.83). Omitting PLND in the low-risk group would have spared 368 (49.2{\%}) of the entire cohort with a false-negative rate of 5/369 (1.3{\%}) for the low-risk group, and 5/760 (0.7{\%}) for the entire cohort. Sensitivity was 88.4{\%}, and negative predictive value was 98.7{\%}. Conclusion: Patients can be risk stratified for node-positive disease and potentially excluded from lymphadenectomy with minimal risk.",
author = "Pettus, {Joseph A.} and Timothy Masterson and Abel, {E. Jason} and Middleton, {Richard G.} and Stephenson, {Robert A.}",
year = "2008",
month = "5",
day = "1",
doi = "10.1089/end.2007.0129",
language = "English (US)",
volume = "22",
pages = "1021--1025",
journal = "Journal of Endourology",
issn = "0892-7790",
publisher = "Mary Ann Liebert Inc.",
number = "5",

}

TY - JOUR

T1 - Risk stratification for positive lymph nodes in prostate cancer

AU - Pettus, Joseph A.

AU - Masterson, Timothy

AU - Abel, E. Jason

AU - Middleton, Richard G.

AU - Stephenson, Robert A.

PY - 2008/5/1

Y1 - 2008/5/1

N2 - Purpose: To evaluate the risk of positive lymph nodes using preoperative clinical parameters. Methods and Materials: We reviewed our prospectively collected database for all patients who received RRP and PLND between January 1993 and November 2005 as primary therapy for prostate cancer. We excluded patients who had hormonal ablation or radiation therapy prior to surgery and patients with missing PSA, clinical stage, or biopsy Gleason score. We evaluated risk for nodal disease using the following definitions: low risk: PSA ≤10 ng/mL, clinical stage ≤T2a, and Gleason score ≤6; intermediate risk: PSA 10 to 20 ng/mL, clinical stage ≥T2b, or Gleason score of 7; and high risk: PSA ≥20 ng/mL, or clinical stage ≥T2c, or Gleason score ≥8. Logistic regression was used to determine the association between the risk groups and pathologic lymph node involvement, and a receiver operating characteristics (ROC) curve was constructed to evaluate the performance of the stratification scheme in detecting nodal disease. Results: A total of 760 patients with 43 (5.7%) patients with node-positive disease were available for analysis. Risk classification was significantly associated with positive nodes (P <0.001), even after controlling for year of surgery and age. The area under the ROC curve was 0.77 (95% CI: 0.69, 0.83). Omitting PLND in the low-risk group would have spared 368 (49.2%) of the entire cohort with a false-negative rate of 5/369 (1.3%) for the low-risk group, and 5/760 (0.7%) for the entire cohort. Sensitivity was 88.4%, and negative predictive value was 98.7%. Conclusion: Patients can be risk stratified for node-positive disease and potentially excluded from lymphadenectomy with minimal risk.

AB - Purpose: To evaluate the risk of positive lymph nodes using preoperative clinical parameters. Methods and Materials: We reviewed our prospectively collected database for all patients who received RRP and PLND between January 1993 and November 2005 as primary therapy for prostate cancer. We excluded patients who had hormonal ablation or radiation therapy prior to surgery and patients with missing PSA, clinical stage, or biopsy Gleason score. We evaluated risk for nodal disease using the following definitions: low risk: PSA ≤10 ng/mL, clinical stage ≤T2a, and Gleason score ≤6; intermediate risk: PSA 10 to 20 ng/mL, clinical stage ≥T2b, or Gleason score of 7; and high risk: PSA ≥20 ng/mL, or clinical stage ≥T2c, or Gleason score ≥8. Logistic regression was used to determine the association between the risk groups and pathologic lymph node involvement, and a receiver operating characteristics (ROC) curve was constructed to evaluate the performance of the stratification scheme in detecting nodal disease. Results: A total of 760 patients with 43 (5.7%) patients with node-positive disease were available for analysis. Risk classification was significantly associated with positive nodes (P <0.001), even after controlling for year of surgery and age. The area under the ROC curve was 0.77 (95% CI: 0.69, 0.83). Omitting PLND in the low-risk group would have spared 368 (49.2%) of the entire cohort with a false-negative rate of 5/369 (1.3%) for the low-risk group, and 5/760 (0.7%) for the entire cohort. Sensitivity was 88.4%, and negative predictive value was 98.7%. Conclusion: Patients can be risk stratified for node-positive disease and potentially excluded from lymphadenectomy with minimal risk.

UR - http://www.scopus.com/inward/record.url?scp=43749090417&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43749090417&partnerID=8YFLogxK

U2 - 10.1089/end.2007.0129

DO - 10.1089/end.2007.0129

M3 - Article

VL - 22

SP - 1021

EP - 1025

JO - Journal of Endourology

JF - Journal of Endourology

SN - 0892-7790

IS - 5

ER -